RxDoctor Payments Data

Andrew Parks, MD

Family Medicine · New Roads, LANPI 1710372974

Payments from drug & device makers

$7,231in general payments, 2019–2025

Across 479 payments — averaging $15.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$733
  • Novo Nordisk$703
  • Pfizer$473
  • Takeda Pharmaceuticals U.S.A., Inc.$395
  • Abbott$312
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$7,210100%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,231 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$3,412
Medicare patients
31
Services billed
238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide114$156,139
OzempicSemaglutide90$118,474
JanuviaSitagliptin Phosphate122$116,666
JardianceEmpagliflozin94$110,365
EliquisApixaban96$85,094
Trelegy ElliptaFluticasone/Umeclidin/Vilanter96$76,058
FarxigaDapagliflozin Propanediol60$61,712
LinzessLinaclotide78$55,209
Tresiba Flextouch U-100Insulin Degludec38$26,720
Soliqua 100-33Insulin Glargine/Lixisenatide24$25,853
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog25$23,398
TrulicityDulaglutide16$19,288
VraylarCariprazine Hcl13$19,207
Repatha SureclickEvolocumab19$17,691
MyrbetriqMirabegron39$17,540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$733$175,427130 claims
Novo NordiskOzempic$703$118,47490 claims
MerckJanuvia$132$116,666122 claims
Boehringer IngelheimJardiance$179$110,36594 claims
PfizerEliquis$473$85,09496 claims
GSKTrelegy Ellipta$169$76,05896 claims
AbbVieLinzess, Vraylar$1,481$74,41691 claims
AstraZenecaFarxiga, Breztri Aerosphere$186$71,22973 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$245$25,85324 claims
Astellas Pharma US IncMyrbetriq$139$17,54039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in New Roads

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →